Apertura and FAST Partner on Angelman Gene Therapy Innovation
Austin, Texas & New York, August 5, 2026 The Foundation for Angelman Syndrome Therapeutics (FAST) has announced a strategic...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Austin, Texas & New York, August 5, 2026 The Foundation for Angelman Syndrome Therapeutics (FAST) has announced a strategic...
New York, August 4, 2026 AEYE Health has announced the publication of a real-world clinical study in the British...
